Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEmily McGovernNovartis (Ireland)DLDominick Latrémouille-ViauGroup for Research in Decision AnalysisNGNathan GobeilGroup for Research in Decision Analysis

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals asciminib shows better MR3 and MR4 rates in chronic myeloid leukemia patients, suggesting improved efficacy in clinical practice.

Key Points

  • This study compares real-world outcomes of asciminib and ATP-competitive TKIs as second-line treatments in CML-CP patients.
  • Retrospective chart review of patients across US oncology sites.
  • Collected patient data on demographics, treatment response, and comorbidities.
  • Utilized Kaplan-Meier methods to assess time to molecular response and treatment discontinuation.
  • Asciminib cohort showed 68.3% achieving MR3 compared to 58.1% in the comparison cohort (p<0.05).
  • Median time to MR3 was shorter for asciminib (30.7 weeks) than for ATP-competitive TKIs (39.7 weeks).
  • Lower discontinuation rates due to intolerance were seen in asciminib patients (1.6% vs 3.6%).

Cite This Study

McGovern et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e47ehttps://doi.org/10.1182/blood-2025-724
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Favorable tolerability of asciminib &lt;i&gt;versus&lt;/i&gt; ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia2026
  2. 2Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025
  3. 3Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review2026
  4. 4Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results2024 · 55 citations
  5. 5Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase2025